Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine, Inc. (NASDAQ: IRON) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its clinical-stage biopharmaceutical business focused on serious hematologic diseases. These SEC filings cover financial results, capital-raising transactions, regulatory milestones, and key corporate events related to the company’s investigational programs in red blood cell biology, heme biosynthesis, and iron homeostasis.
Among the most frequently referenced documents are current reports on Form 8-K, where Disc Medicine discloses material events such as quarterly financial results, public offerings of common stock and pre-funded warrants, and significant regulatory developments. For example, the company has used 8-K filings to report a Commissioner’s National Priority Voucher from the U.S. Food and Drug Administration for bitopertin in erythropoietic protoporphyria, the submission of a New Drug Application under the accelerated approval pathway, and the terms of an underwriting agreement for an upsized public offering intended to support operations and development plans.
Investors also look to Disc Medicine’s periodic reports on Forms 10-K and 10-Q for comprehensive discussions of its pipeline, including bitopertin, DISC-0974, and DISC-3405, as well as risk factors and management’s analysis of financial condition. Filings may describe clinical trial status, patent coverage such as composition of matter protection for DISC-0974, and the company’s expectations regarding cash runway based on existing cash, cash equivalents, marketable securities, and offering proceeds.
On this page, users can access Disc Medicine’s SEC filings as they are made available through EDGAR. AI-powered tools can help summarize lengthy documents, highlight key sections on topics such as clinical development, financing terms, and forward-looking statements, and make it easier to understand how individual filings relate to the company’s broader strategy and risk profile. Forms 10-K, 10-Q, and 8-K, along with exhibits, provide the primary regulatory record for IRON and are central to in-depth fundamental research.
Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 24,962 shares of common stock, with an aggregate market value of $1,473,506.86, to be sold through Merrill Lynch One Bryant Park, New York on Nasdaq with an approximate sale date of 08/13/2025. The filing states the shares were acquired in a private placement from the issuer on 05/01/2020 and paid in cash on that date.
The form also lists multiple sale transactions by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. during July and August 2025, including a sale of 53,215 shares on 07/23/2025 for $3,244,656.91. The filing reports 34,765,581 shares outstanding for the issuer. No signature date or additional issuer relationship details are provided in the extract.
Disc Medicine (IRON) filed a Form 144 proposing the sale of 44,520 shares of common stock with an aggregate market value of $2,628,015.60, to be sold through Merrill Lynch on Nasdaq. The shares were acquired in a private placement on 05/01/2020 and the filing lists an approximate sale date of 08/13/2025. The filing also discloses multiple recent dispositions by Atlas Venture-related funds: a total of 145,916 shares sold in the past three months, generating approximately $8,905,720.24 in gross proceeds. The issuer has 34,765,581 shares outstanding per the form.
Wellington Management and affiliated entities report beneficial ownership of 1,432,090 shares of Disc Medicine, Inc. common stock, representing 4.13% of the class. The filing shows shared voting power over 1,074,282 shares and shared dispositive power over 1,432,090 shares; sole voting and dispositive powers are reported as 0. The securities are owned of record by clients of the listed Wellington investment advisers and are held in the ordinary course of business. The filing identifies Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP as reporting entities and lists the relevant Wellington investment adviser subsidiaries that manage the client accounts holding these shares.
Disc Medicine (NASDAQ: IRON) filed its Q2-25 Form 10-Q. The clinical-stage biotech remains pre-revenue and focuses on hematologic programs bitopertin, DISC-0974 and DISC-3405.
- Cash, cash equivalents and marketable securities rose to $650.0 million (Dec-24: $489.9 m), driven by a January 2025 equity raise that netted $243 m.
- Q2 operating loss widened to $61.4 m (Q2-24: $30.9 m) as R&D expense nearly doubled to $46.3 m; SG&A increased to $15.1 m.
- Net loss was $55.3 m, or –$1.58/sh; 6-month loss was $89.3 m.
- Term-loan debt totals $30 m (net carrying value $28.7 m) under a Hercules facility maturing 2029; minimum-cash covenant waived while market cap ≥$1 bn.
- Milestone outflows: $10 m to Roche (Phase 3 start) and $3 m to AbbVie (Phase 2 start).
- Runway: management states funds are sufficient for at least 12 months and to support planned NDA submission (Oct-25) seeking accelerated approval of bitopertin for EPP/XLP.
Key pipeline events: APOLLO Phase 3 trial of bitopertin initiated May-25; Phase 2 readouts for DISC-0974 (MF & CKD anemia) expected 2H-25. The company also completed an asset acquisition (clinic-ready MDS program) with up to $50 m contingent payments.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
